Gyre Therapeutics, Inc. (GYRE) Q4 Results Fall Short of Expectations

Gyre Therapeutics, Inc. Reports Fourth Quarter Earnings

Gyre Therapeutics, Inc. (GYRE) announced earnings of $0.04 per share for the latest quarter, which fell short of the Zacks Consensus Estimate of $0.08 per share. In comparison, the company reported earnings of $0.01 per share during the same period last year. These results have been adjusted to exclude one-time items.

This quarter's performance resulted in a negative earnings surprise of 50%. In the previous quarter, Gyre was projected to earn $0.05 per share but actually achieved $0.06, marking a positive surprise of 20%.

Looking at the past year, Gyre Therapeutics has only exceeded consensus earnings per share estimates once in the last four quarters.

Operating within the Zacks Medical - Biomedical and Genetics sector, Gyre Therapeutics posted quarterly revenues of $37.2 million for the period ending December 2025, surpassing analyst expectations by 2.17%. This is an increase from $27.87 million in revenue reported a year earlier. Over the last four quarters, the company has beaten revenue forecasts twice.

The immediate reaction of Gyre’s stock price to these results, as well as its future trajectory, will largely depend on insights shared by management during the earnings call.

Since the start of the year, shares of Gyre Therapeutics have climbed approximately 18%, while the S&P 500 has declined by 1% over the same period.

What Lies Ahead for Gyre Therapeutics?

Although Gyre Therapeutics has outperformed the broader market so far this year, investors are now considering what the future holds for the stock.

One key factor to watch is the company’s earnings outlook. This not only includes current consensus projections for upcoming quarters, but also any recent changes to those estimates.

Studies indicate that short-term stock price movements are closely linked to trends in earnings estimate revisions. Investors can monitor these changes themselves or use established tools like the Zacks Rank, which has a strong history of leveraging earnings estimate trends.

Prior to this earnings announcement, analyst estimate revisions for Gyre Therapeutics were mixed. While the latest results may prompt further changes, the stock currently holds a Zacks Rank #3 (Hold), suggesting it is likely to perform in line with the market in the near term.

It remains to be seen how analyst estimates for the next quarters and the full fiscal year will evolve. At present, consensus forecasts call for earnings per share of $0.09 on $44.5 million in revenue for the next quarter, and $0.27 per share on $162 million in revenue for the current year.

Investors should also consider the broader industry outlook, as it can significantly influence stock performance. The Medical - Biomedical and Genetics industry currently ranks in the top 36% of over 250 Zacks-tracked sectors. Research from Zacks shows that the top half of ranked industries tend to outperform the lower half by more than two to one.

Industry Comparison: Adherex Technologies Inc. (FENC)

Another company in the same sector, Adherex Technologies Inc. (FENC), has not yet released its results for the quarter ending December 2025.

Adherex is projected to report quarterly earnings of $0.03 per share, representing a 150% increase from the prior year. Over the past month, the consensus earnings estimate for the quarter has surged by 403.6% to its current level.

The company’s revenue is expected to reach $14.97 million, up 88.7% compared to the same quarter last year.

Is Gyre Therapeutics, Inc. (GYRE) a Good Investment?

Thinking about investing in Gyre Therapeutics, Inc. (GYRE)? For insights on the top stocks to consider over the next month, check out Zacks Investment Research’s complimentary report on the 7 best stocks to buy now.

Since 1978, Zacks Investment Research has provided investors with independent analysis and tools. Over the past 25 years, the Zacks Rank stock-rating system has delivered an average annual return of +24.08%, more than doubling the S&P 500’s performance from January 1, 1988 through May 6, 2024.

Want to see the latest stock picks from Zacks Investment Research? Download the 7 Best Stocks for the Next 30 Days for free.